Blue Longevity Clinic has secured €2 million in funding to bring preventive longevity medicine to Southeast Europe, marking a significant step towards democratizing advanced health optimization services in the region. The Bulgarian-founded startup plans to establish operations across three key markets through an integrated approach combining cutting-edge diagnostics with personalized treatment protocols.
Eleven Ventures led the funding round, with Sofia Angels Ventures and several family offices participating. The investment will support the company’s expansion into Greece, Turkey, and Bulgaria, targeting what founders describe as an underserved market for proactive healthcare solutions.
Targeting Preventive Healthcare Gap
Serial healthcare entrepreneur Ilian Grigorov founded the venture alongside Blagoy Palev and Dr. George Vissarakis to address the growing demand for longevity medicine beyond traditional reactive care models. The company’s approach centres on comprehensive functional testing that evaluates metabolic, genetic, and cognitive biomarkers to identify health risks before symptoms emerge.
“The transition from reactive sick care to proactive health care is no longer a trend, it’s a global shift,” said Valeri Petrov, Partner at Eleven Ventures. The investment thesis reflects growing recognition that Southeast Europe represents an untapped opportunity in the expanding longevity medicine sector.
Integrated Service Model
Blue Longevity differentiates itself through vertical integration, combining in-person diagnostics with personalised therapy modules and digital health tools. Clients undergo comprehensive health profiling before receiving customised treatment plans that may include hyperbaric oxygen therapy, cryotherapy, and red light therapy delivered through company-operated clinics.
The proprietary digital application supports long-term engagement by guiding patients through microhabit formation designed to sustain healthy lifestyle changes. This model addresses what the company identifies as a market gap between diagnostic-only services and non-personalised wellness offerings.
Regional Expansion Strategy
The startup plans to open facilities in Athens, Istanbul, and Sofia by September, capitalising on Southeast Europe’s substantial out-of-pocket health spending patterns. The region’s slower adoption of longevity medicine innovations creates opportunity for early market entry, according to company leadership.
“We’re building a new kind of health centre – one that people don’t just visit once a year, but one that becomes part of their lifestyle,” said Grigorov. The founder’s previous experience includes City Clinic and Blocks Health ventures.
Milen Ivanov, Managing Partner at Sofia Angels Ventures, noted the sector’s potential reach: “Longevity is becoming the new frontier of healthcare – no longer a privilege reserved for eccentric biohackers, reclusive yogis, or billionaires.”
Technology and Clinical Development
The funding will support clinical build-outs, medical team expansion, and further development of the company’s AI-assisted biomarker analysis platform. The technology generates personalised longevity reports under physician oversight, enabling clients to monitor cardiovascular, metabolic, and mental health indicators over time.
The company’s protocol development focuses on early intervention strategies, using genetic testing and biomarker analysis to reduce future disease risk rather than treating existing conditions. This preventive approach aligns with broader healthcare industry trends toward value-based care models.